About Us
Prof. Samir K. Maji
Founder & Director, AmyScan Healthcare
Professor, IIT Bombay
Professor-in-charge, Sunita Sanghi Center of Ageing and
Neurodegenerative Disorders (SCAN)
AmyScan is built on more than a decade of research led by our founder, Prof. Dr. Samir Maji, a global expert in protein misfolding, aggregation, and amyloid biology. Prof. Maji has conducted research at leading institutions including Harvard Medical School, UCLA, the Salk Institute, and ETH Zurich.
Currently a Professor at IIT Bombay and Professor-in-Charge at SCAN, he brings unparalleled expertise in the biology of Parkinson’s and Alzheimer’s to our translational mission—bridging the gap between academic discovery and clinical application.
Minimally
Invasive
Highly
Accurate
Clinically
Validated
Cost
Effective
About Us
AmyScan Healthcare was founded at IIT Bombay, emerging from the pioneering research at the Sunita Sanghi Centre for Ageing and Neurodegenerative Diseases (SCAN) and the Department of Biosciences and Bioengineering. Our mission is to transform the diagnosis of neurodegenerative diseases—starting with Parkinson’s—by making it earlier, more accessible, and more accurate.
At AmyScan Healthcare, our mission is to transform how amyloid-based neurodegenerative diseases are diagnosed, starting with Parkinson’s disease. We are developing minimally invasive, cost-effective blood tests that detect disease-specific amyloid markers at their earliest stages, enabling timely intervention and improved patient outcomes.
What We Do
At the heart of our innovation is the use of patented protein molecules employed using the cutting-edge technology that enables the detection of ultra-low levels of circulating α-synuclein amyloid seeds in blood—a key biomarker of Parkinson’s disease—using a process similar to PCR. Our approach provides highly sensitive and specific results, even when biomarker levels are minimal, empowering clinicians to make faster and more accurate decisions.
Amyscan envisions transforming the diagnosis and management of amyloid-based diseases by translating cutting-edge research into high-throughput and clinically accessible diagnostic tools. We aim to develop detecting tiny amounts of amyloid seeds in circulation and/or secretion for diagnosing various amyloid diseases—one that facilitates timely intervention and paves the way for more effective treatment strategies.
Our Ecosystem
